Abstracts tagged "Leukopenia"

Abstract Number: 1963 • 2019 ACR/ARP Annual Meeting
Combining Clinical and Candidate Gene Data into a Risk Score for Azathioprine-Associated Leukopenia in Routine Clinical Practice
Prathima Anandi ¹, Alyson Dickson ², Qiping Feng ¹, Wei-Qi Wei ², William Dupont ², Dale Plummer ², Ge Liu ¹, Katherine Barker ², Vivian Kawai ², Kelly Birdwell ², Nancy Cox ¹, C. Michael Stein ², Adriana Hung ² and Cecilia Chung³, ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University, Nashville, TN
Background/Purpose: Azathioprine is a widely-used drug for the treatment of rheumatic diseases, inflammatory bowel disease, and for organ transplantation. However, treatment is often limited by…
Abstract Number: 515 • 2017 ACR/ARHP Annual Meeting
Leukopenia and Tumor Necrosis Factor Alpha Inhibitor Therapy
Wenlu Xiong¹, Rochella A. Ostrowski², William Adams³ and Rodney Tehrani⁴, ¹Rheumatology, Vanderbilt University Medical Center, Nashville, TN, ²Rheumatology, Loyola University Medical Center, Maywood, IL, ³Clinical Research Office, Loyola University Medical Center, Maywood, IL, ⁴Rheumatology & Immunology, Loyola University Medical Center, Maywood, IL
- Background/Purpose: Tumor necrosis factor (TNF) alpha, a key proinflammatory cytokine in rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), has been a major target in…
Abstract Number: 1629 • 2017 ACR/ARHP Annual Meeting
Disease Activity Is an Independent Predictor of Leukopenia in a Large International SLE Cohort
Rangi Kandane-Rathnayake¹, Vera Golder², Worawit Louthrenoo³, Sargunan Sockalingam⁴, Aisha Lateef⁵, Yuan An⁶, Leonid Zamora⁷, Yeong-Jian Wu⁸, Shue-Fen Luo⁹, Madelynn Chan¹⁰, Fiona Goldblatt¹¹, Chak Sing Lau¹², Zhan-Guo Li¹³, Sandra V. Navarra⁷, Mandana Nikpour¹⁴, Eric F Morand¹⁵ and Alberta Y. Hoi², ¹Rheumatology, Monash University, Melbourne, Australia, ²Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, ³Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁴University of Malaya, Kuala Lumpur, Malaysia, ⁵Medicine, Division of Rheumatology, National University Hospital of Singapore, Singapore, Singapore, ⁶Peking University People's Hospital, Beijing, China, ⁷Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ⁸Chang Gung University, Taoyuan County, Taiwan, ⁹Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ¹⁰Tan Tock Seng Hospital, Singapore, Singapore, ¹¹Flinders University, Adelaide, Australia, ¹²Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ¹³Peking University International Hospital, Beijing, China, ¹⁴Melbourne University, Melbourne, Australia, ¹⁵Monash University, Melbourne, Australia
Background/Purpose: Leukopenia is commonly seen in SLE, but its predictors are not well understood, as it can be a result of disease activity or bone…
Abstract Number: 2381 • 2017 ACR/ARHP Annual Meeting
Hematologic Abnormalities during the Use of Low Dose Methotrexate for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Kathleen Vanni¹, Zhi Zhang¹, Cassandra Corrigan² and Daniel H. Solomon³, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Methotrexate (MTX) is known to increase the risk of cytopenias, but the prevalence of hematologic abnormalities among patients taking low dose MTX is poorly…
Abstract Number: 2183 • 2012 ACR/ARHP Annual Meeting
Common Features in Lymphoproliferative Complications in the Course of Primary Sjögren’s Syndrome: Results From a Multicenter Cohort of 1170 Patients
Luca Quartuccio¹, Chiara Baldini², Roberta Priori³, Elena Bartoloni Bocci⁴, Francesco Carubbi⁵, Miriam Isola⁶, Marta Maset⁷, Sara Salvin⁷, Nicoletta Luciano², Giovanna Picarelli⁸, Alessia Alunno⁹, Roberto Giacomelli¹⁰, Roberto Gerli¹¹, Guido Valesini¹², Stefano Bombardieri¹³ and Salvatore De Vita¹, ¹Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Italy, ³Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁴Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy, ⁵Rheumatology Clinic, University of L'Aquila, L'Aquila, Italy, ⁶Institute of Statistics, University of Udine, Udine, Italy, ⁷Rheumatology Clinic, DSMB, University of Udine, Italy, Udine, Italy, ⁸Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ⁹Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ¹⁰Rheumatology Unit, University of Aquila, L'Aquila, Italy, ¹¹Rheumatology Unit, University of Perugia, Perugia, Italy, ¹²Clinica e Terapia Medica, Sapienza, Universita di Roma, Rome, Italy, ¹³Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: To describe the prevalence of lymphoproliferative complications (defined as B-cell lymphoma or definite conditions predisposing to lymphoma, i.e, cryoglobulinemic vasculitis (CV) and major salivary…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].